What Is Drawing Fresh Attention To Vertex Pharmaceuticals (VRTX)?
Vertex Pharmaceuticals stock moves on inaxaplin kidney data
Vertex Pharmaceuticals (VRTX) drew fresh attention after reporting Phase 2b AMPLIFIED results for inaxaplin in APOL1-mediated kidney disease, with the stock reacting to both the efficacy data and the completion of pivotal trial enrollment.
Vertex Pharmaceuticals shares trade at US$516.34 after the inaxaplin update, with a 30-day share price return of negative 6.6%, a 90-day share price return of positive 5.09%, and a 1-year total shareholder return of 35.21%.
Scan which other kidney and rare disease players are gaining traction after Vertex Pharmaceuticals' inaxaplin update by comparing them against our hand picked 38 healthcare AI stocks.
Vertex Pharmaceuticals now trades near US$516 after a mixed short term share move on the inaxaplin update. Does that recent pullback leave enough upside in the risk reward to still attract new buyers?
Most Popular Narrative: 7.6% Undervalued
Against Vertex Pharmaceuticals' last close of $516.34, the most followed narrative pegs fair value at $558.68, suggesting a modest valuation gap that hinges on how the broader pipeline and new therapies play out.
Vertex's pipeline diversification, including programs in pain, kidney, and type 1 diabetes, leverages global advances in genomic and gene-editing technologies, positioning the company to capture long-term growth from accelerating personalized and precision medicine adoption, supporting both revenue and long-term margin expansion.
See why 131 investors see Vertex Pharmaceuticals as 8% undervalued.
Result: Fair Value of $558.68 (UNDERVALUED)
Still, the narrative around Vertex Pharmaceuticals can unravel quickly if heavy dependence on cystic fibrosis drugs collides with tougher drug pricing or key pipeline setbacks in areas such as pain or gene editing.
Find out about the key risks to this Vertex Pharmaceuticals narrative.
Another View on Vertex Pharmaceuticals Valuation
Our DCF model offers a different perspective compared with a simple fair value approach. On those cash flow assumptions, Vertex Pharmaceuticals shares trade about 24.3% below an estimated $681.83 per share, which suggests a deeper undervaluation. So which lens do you rely on when real money is at stake?
Look into how the SWS DCF model arrives at its fair value.
Next Steps
Mixed views on Vertex Pharmaceuticals are clear in the numbers, so move quickly, review the underlying data, and decide whether the potential rewards justify the risks by checking the 3 key rewards.
Looking for more investment ideas beyond Vertex Pharmaceuticals?
Do not let your research stop with Vertex Pharmaceuticals. Broaden your watchlist with fresh ideas that match your risk comfort and return goals.
- Hunt for potential turnaround opportunities by scanning focused lists of higher risk, higher potential ideas using the 9 elite penny stocks with strong financials.
- Zero in on quality businesses that may trade below their estimated worth by filtering through the 30 high quality undervalued stocks.
- Prioritize resilience and capital preservation by reviewing companies screened for stronger financial footing via the 31 resilient stocks with low risk scores.
This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.
Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com